lifestyle.pspl.com

Author: SAB Biotherapeutics, Inc.

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

May 7, 2026
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

May 5, 2026
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

May 4, 2026
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

May 2, 2026
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

May 1, 2026
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

April 30, 2026
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

April 30, 2026
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

April 29, 2026
SAB BIO to Participate in Upcoming Investor Conferences

March 2, 2026
SAB BIO to Participate in Upcoming Investor Conferences

February 11, 2026